The Medical Letter on Drugs and Therapeutics
Clindamycin-Tretinoin (Veltin Gel) for Acne
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Veltin Gel (Stiefel), a fixed-dose combination of the antibiotic clindamycin phosphate 1.2% and the retinoid tretinoin 0.025%, has been approved by the FDA for topical treatment of acne vulgaris in patients ≥12 years old. Another product containing the same active ingredients (Ziana) has been on the market since 2006.

TREATMENT OF ACNE — Depending on the severity and type of acne, treatment options range from topical drugs to systemic therapy with antibiotics or retinoids.1

The topical antibiotics clindamycin and erythromycin are commonly used to treat mild to moderate acne and are equally effective. Both have antibacterial and anti-inflammatory properties, but bacterial resistance can occur. The use of benzoyl peroxide, a topical oxidizing agent available without a prescription, with topical antibiotics may decrease the emergence of resistant ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Clindamycin-Tretinoin (Veltin Gel) for Acne
Article code: 1353d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian